Indo Us Biotech Limited has expanded its board with the appointment of Hemanshi Darsh Soni as an Additional Director in the capacity of Non-Executive Independent Director, effective 21 April 2026 for a term of five years, subject to shareholder approval. The board took the decision on 21.04.2026, signaling a deliberate push to strengthen independent oversight as the company advances its growth agenda. Hemanshi Darsh Soni is described in the filing as not related to any director or key managerial personnel and as someone with a background in building high-performance teams, scaling sales, marketing and service networks, and implementing robust operational processes. She does not hold a directorship in any other listed entity and is not debarred from holding office by SEBI; she will serve as an Additional Director pending shareholder consent.
The appointment adds an independent voice to the board, complementing Indo Us Biotech’s leadership team led by Managing Director Jagdish Ajudiya. The five-year term starts from 21 April 2026, aligning with governance norms intended to bolster strategic oversight as the company pursues its initiatives in the life sciences space.